Healthtech startup C-mo Medical Solutions has just secured new funding to bring its cough monitoring to the market, reimagining approaches from diagnosis to treatment all the way to disease management.
Having a cough is something each and every one of us goes through at some point or another. During the height of the pandemic, we all became acutely aware of what dangers a cough could mean – and we are still more aware and conscious of coughing. What we might think is just an irritating setback for the day, could have insights into our wider respiratory health.
Diogo Tecelão, co-founder and CEO of the company, explained: “Chronic cough is a highly prevalent symptom, being responsible for up to 40% of the pulmonologists’ workload. At the same time, cough is a symptom that hides extremely valuable information about the patient’s health, thus bringing tremendous clinical value. The European Respiratory Society stated in 2019 that there is an urgent need for suitable cough monitoring technologies – developing a solution has been our mission since!”
Almada-based C-mo Medical Solutions want to harness that power and have developed a solution for the diagnosis and management of cough-incident medical conditions. The startup has recently raised €4.1 million.
Funding details
- €4.1 million raised in a seed investment round
- The round was led by Boehringer Ingelheim Venture Fund with the participation of Portugal Ventures and High-Tech Gründerfonds.
- It’s the company’s first raise, after previously being awarded by the European Institute of Innovation & Technology for Health and by the Portuguese Innovation Agency.
Dr. Alexander Ehlgen, Investment Manager at Boehringer Ingelheim Venture Fund: “We are excited about the novel C-mo technology in analyzing cough and think that it will provide great value by allowing for a more specific diagnosis, and by empowering patients to better understand and manage their disease”.
Founded by Diogo Tecelão, Miguel Andrade, Filipe Valadas, Alexandra Lopes, Sara Lobo, and Nuno Neuparth, C-mo Medical Solutions is on a mission to harness the potential of cough assessment through digital tech.
Launched in 2019, C-mo’s tech analyzes the characteristics of a patient’s cough and translates them into actionable insights. These insights can be used to accelerate diagnosis, optimize treatment courses, improve disease management and support pharmaceutical research.
Diogo Tecelão: “C-mo is the first and only solution that can monitor the patient’s cough seamlessly, over long periods of time, and while protecting the patient’s privacy. It is also the first tool providing a complete and holistic assessment of the patient’s cough traits, thus enabling its application in several key use cases”.
Now, with this new funding in the bank, the Portuguese innovators want to bring its cough-monitoring tech to the market.
Diogo Tecelão: “We are excited to bring onboard strategic and valuable investors that share our vision. We believe C-mo will cause a paradigm shift on how coughs are addressed, respiratory diseases are monitored, and new drugs are launched to the market.”
Niels Sharman, Investment Manager at High-Tech Gründerfonds: “C-mo is addressing an unmet clinical need. Its solution has the potential to significantly improve how cough-related diseases are diagnosed, managed and treated. This seed round will enable the company to obtain key clinical evidence and to further develop its platform. We look forward to supporting the team on its journey.”
Teresa Fiúza, Executive Vice President of Portugal Ventures: “We’re proud to be investing in C-mo Medical Solutions. This round will enable the company to continue developing their product and meeting the medical needs related to the personalized management of chronic cough and doctor-patient interactions, alongside internationalization to the European and US markets”
via https://www.AiUpNow.com
January 31, 2023 at 05:41AM by contact@bcurdy.com (Patricia Allen), Khareem Sudlow
